Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
- Revenue in USD (TTM)236.65m
- Net income in USD-313.72m
- Incorporated1999
- Employees597.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 655-5049
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanara Medtech Inc | 68.00m | -4.89m | 273.42m | 107.00 | -- | 6.31 | -- | 4.02 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 293.38m | 159.00 | -- | 7.21 | -- | 3.25 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 303.16m | 135.00 | -- | -- | -- | 5.89 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Scilex Holding Co | 47.05m | -160.60m | 309.83m | 106.00 | -- | -- | -- | 6.59 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 318.15m | 100.00 | -- | 210.98 | -- | 35.70 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 325.24m | 45.00 | -- | 2.87 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 376.57m | 377.00 | -- | -- | -- | 2.20 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 415.64m | 357.00 | -- | 1.99 | -- | 2.46 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Precigen Inc | 5.44m | -96.91m | 416.49m | 202.00 | -- | 4.26 | -- | 76.58 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 443.34m | 240.00 | -- | -- | -- | 1.93 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 453.31m | 597.00 | -- | -- | -- | 1.92 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | 396,390.30 | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 490.22m | 99.00 | -- | 2.39 | -- | 7.97 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 498.19m | 121.00 | -- | 1.91 | -- | 9.96 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Avid Bioservices Inc | 139.91m | -140.75m | 594.48m | 371.00 | -- | 9.76 | -- | 4.25 | -2.22 | -2.22 | 2.21 | 0.9579 | 0.355 | 3.57 | 4.92 | 377,118.60 | -35.72 | -0.826 | -56.03 | -1.20 | 5.23 | 19.26 | -100.60 | -2.14 | 1.04 | -4.30 | 0.727 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| SNDL Inc | 656.20m | -99.03m | 605.21m | 2.52k | -- | 0.68 | -- | 0.9223 | -0.3783 | -0.387 | 2.51 | 3.37 | 0.5855 | 4.67 | 33.35 | 260,809.30 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
52.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 13.95m | 13.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.55m | 6.27% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 6.24m | 5.98% |
| GIC Pte Ltd. (Investment Management)as of 08 Mar 2024 | 5.83m | 5.58% |
| Palo Alto Investors LPas of 31 Mar 2024 | 5.25m | 5.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.17m | 4.95% |
| Polar Capital LLPas of 31 Mar 2024 | 3.88m | 3.72% |
| Barclays Capital, Inc.as of 31 Mar 2024 | 2.92m | 2.80% |
| Rubric Capital Management LPas of 31 Mar 2024 | 2.66m | 2.54% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.36m | 2.26% |
More ▼
Data from 31 Mar 2024 - 10 Jul 2024Source: FactSet Research Systems Inc.
